Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

AMPK directly activates mTORC2 to promote cell survival during acute energetic stress.

Kazyken D, Magnuson B, Bodur C, Acosta-Jaquez HA, Zhang D, Tong X, Barnes TM, Steinl GK, Patterson NE, Altheim CH, Sharma N, Inoki K, Cartee GD, Bridges D, Yin L, Riddle SM, Fingar DC.

Sci Signal. 2019 Jun 11;12(585). pii: eaav3249. doi: 10.1126/scisignal.aav3249.

PMID:
31186373
2.

The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.

Bodur C, Kazyken D, Huang K, Ekim Ustunel B, Siroky KA, Tooley AS, Gonzalez IE, Foley DH, Acosta-Jaquez HA, Barnes TM, Steinl GK, Cho KW, Lumeng CN, Riddle SM, Myers MG Jr, Fingar DC.

EMBO J. 2018 Jan 4;37(1):19-38. doi: 10.15252/embj.201696164. Epub 2017 Nov 17.

3.

Pharmacological targeting of the pseudokinase Her3.

Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS.

Nat Chem Biol. 2014 Dec;10(12):1006-12. doi: 10.1038/nchembio.1658. Epub 2014 Oct 19.

4.

LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status.

Reynolds A, Doggett EA, Riddle SM, Lebakken CS, Nichols RJ.

Front Mol Neurosci. 2014 Jun 24;7:54. doi: 10.3389/fnmol.2014.00054. eCollection 2014.

5.

Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain.

Liao J, Wu CX, Burlak C, Zhang S, Sahm H, Wang M, Zhang ZY, Vogel KW, Federici M, Riddle SM, Nichols RJ, Liu D, Cookson MR, Stone TA, Hoang QQ.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4055-60. doi: 10.1073/pnas.1323285111. Epub 2014 Mar 3.

6.

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.

O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ.

Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10.

7.

Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.

Zhao J, Hermanson SB, Carlson CB, Riddle SM, Vogel KW, Bi K, Nichols RJ.

Biochem Soc Trans. 2012 Oct;40(5):1158-62. Review.

PMID:
22988882
8.

Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.

Hermanson SB, Carlson CB, Riddle SM, Zhao J, Vogel KW, Nichols RJ, Bi K.

PLoS One. 2012;7(8):e43580. doi: 10.1371/journal.pone.0043580. Epub 2012 Aug 28.

9.

Detection of allosteric kinase inhibitors by displacement of active site probes.

Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM.

J Biomol Screen. 2012 Jul;17(6):813-21. doi: 10.1177/1087057112439889. Epub 2012 Mar 26.

PMID:
22453235
10.

A substrate-independent TR-FRET histone deacetylase inhibitor assay.

Marks BD, Fakhoury SA, Frazee WJ, Eliason HC, Riddle SM.

J Biomol Screen. 2011 Dec;16(10):1247-53. doi: 10.1177/1087057111422102. Epub 2011 Sep 21.

PMID:
21940713
11.

Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.

Lebakken CS, Riddle SM, Singh U, Frazee WJ, Eliason HC, Gao Y, Reichling LJ, Marks BD, Vogel KW.

J Biomol Screen. 2009 Sep;14(8):924-35. doi: 10.1177/1087057109339207. Epub 2009 Jun 29.

PMID:
19564447
12.

Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.

Reichling LJ, Riddle SM.

Biochem Biophys Res Commun. 2009 Jun 26;384(2):255-8. doi: 10.1016/j.bbrc.2009.04.098. Epub 2009 May 3.

PMID:
19397894
13.

Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.

Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst WD, Riddle SM, Braithwaite SP.

FEBS J. 2009 Jan;276(2):466-78. doi: 10.1111/j.1742-4658.2008.06789.x.

14.

Pharmacological characterization of purified recombinant mTOR FRB-kinase domain using fluorescence-based assays.

Reichling LJ, Lebakken CS, Riddle SM, Vedvik KL, Robers MB, Kopp LM, Bruinsma R, Vogel KW.

J Biomol Screen. 2008 Mar;13(3):238-44. doi: 10.1177/1087057108314609.

PMID:
18354135
15.

Homogenous fluorescent assays for characterizing small-molecule activators of AMP-activated protein kinase (AMPK).

Reichling LJ, Riddle SM, Mei B, Bruinsma R, Goossens TA, Huwiler KG, Maffitt M, Newport AM, Qian XD, Ruttimann-Johnson C, Vogel KW.

Curr Chem Genomics. 2008 Feb 25;1:34-42. doi: 10.2174/1875397300801010034.

16.

The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS.

Biochemistry. 2007 Jan 23;46(3):683-95.

PMID:
17223690
17.

A substrate for deubiquitinating enzymes based on time-resolved fluorescence resonance energy transfer between terbium and yellow fluorescent protein.

Horton RA, Strachan EA, Vogel KW, Riddle SM.

Anal Biochem. 2007 Jan 1;360(1):138-43. Epub 2006 Aug 10.

PMID:
17118327
19.

Structural basis for the specificity of ubiquitin C-terminal hydrolases.

Johnston SC, Riddle SM, Cohen RE, Hill CP.

EMBO J. 1999 Jul 15;18(14):3877-87.

Supplemental Content

Loading ...
Support Center